Literature DB >> 20169470

Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease.

Sang J Na1, Anthony G DiLella, Edward V Lis, Keith Jones, David M Levine, David J Stone, J F Hess.   

Abstract

Convection enhanced delivery of 6-hydroxydopamine (6-OHDA) to the rat striatum results in a model of Parkinson's disease. An important feature of this unilateral model is the progressive loss of dopaminergic (DA) neurons over the course of several weeks. To improve the understanding of this model, gene expression changes in the substantia nigra, which contains the DA neuron cell bodies, and the striatum, which contains the DA neuron synaptic terminals, were examined using DNA microarrays. Samples were collected and behavior was analyzed from vehicle and toxin treated animals at 3 days, 1 week, 2 weeks and 4 weeks following 6-OHDA treatment. Tissue DA content was determined and samples from animals which exhibited a substantial depletion of striatal DA were included in the subsequent gene expression analysis. The results of the gene expression analysis indicated that 6-OHDA elicits a vigorous inflammatory response, comprised of several distinct pathways, in the striatum at the earliest time point tested. In contrast, relatively few gene expression changes were observed in the SN at the 3-day time point. In both tissues examined there was evidence for a vigorous inflammatory response at the 1- and 2-week time points, which was substantially diminished by the 4-week time point. Inflammation plays a prominent role in the 6-OHDA model of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20169470     DOI: 10.1007/s11064-010-0133-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  27 in total

Review 1.  Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs.

Authors:  Silvia Mandel; Orly Weinreb; Moussa B H Youdim
Journal:  Trends Pharmacol Sci       Date:  2003-04       Impact factor: 14.819

Review 2.  The role and expression of the protocadherin-alpha clusters in the CNS.

Authors:  Teruyoshi Hirayama; Takeshi Yagi
Journal:  Curr Opin Neurobiol       Date:  2006-05-11       Impact factor: 6.627

3.  The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig.

Authors:  L Piali; C Weber; G LaRosa; C R Mackay; T A Springer; I Clark-Lewis; B Moser
Journal:  Eur J Immunol       Date:  1998-03       Impact factor: 5.532

4.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Authors:  Michael A Hauser; Yi-Ju Li; Hong Xu; Maher A Noureddine; Yujun S Shao; Steven R Gullans; Clemens R Scherzer; Roderick V Jensen; Adam C McLaurin; Jason R Gibson; Burton L Scott; Rita M Jewett; Judith E Stenger; Donald E Schmechel; Christine M Hulette; Jeffery M Vance
Journal:  Arch Neurol       Date:  2005-06

Review 5.  Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems.

Authors:  Renee M Miller; Howard J Federoff
Journal:  Neuroscientist       Date:  2005-12       Impact factor: 7.519

Review 6.  Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

Authors:  Andreas Schober
Journal:  Cell Tissue Res       Date:  2004-07-28       Impact factor: 5.249

7.  Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry.

Authors:  K Seroogy; M Schalling; S Brené; A Dagerlind; S Y Chai; T Hökfelt; H Persson; M Brownstein; R Huan; J Dixon
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

8.  Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease.

Authors:  Mark H Chin; Wei-Jun Qian; Haixing Wang; Vladislav A Petyuk; Joshua S Bloom; Daniel M Sforza; Goran Laćan; Dahai Liu; Arshad H Khan; Rita M Cantor; Diana J Bigelow; William P Melega; David G Camp; Richard D Smith; Desmond J Smith
Journal:  J Proteome Res       Date:  2008-02       Impact factor: 4.466

9.  Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum.

Authors:  Maddalena Napolitano; Diego Centonze; Angelica Calce; Barbara Picconi; Stefania Spiezia; Alberto Gulino; Giorgio Bernardi; Paolo Calabresi
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

10.  Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways.

Authors:  David M Levine; David R Haynor; John C Castle; Sergey B Stepaniants; Matteo Pellegrini; Mao Mao; Jason M Johnson
Journal:  Genome Biol       Date:  2006-10-17       Impact factor: 13.583

View more
  13 in total

1.  Neurotoxin-Induced Catecholaminergic Loss in the Colonic Myenteric Plexus of Rhesus Monkeys.

Authors:  Jeanette M Shultz; Henry Resnikoff; Viktorya Bondarenko; Valerie Joers; Andres Mejia; Heather Simmons; Marina E Emborg
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-11-03

2.  Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.

Authors:  Bing Cao; Yanqiu Zhang; Jinhu Chen; Pengyue Wu; Yuxuan Dong; Yanqin Wang
Journal:  Metab Brain Dis       Date:  2021-11-24       Impact factor: 3.584

3.  Movement Disorder and Neurotoxicity Induced by Chronic Exposure to Microcystin-LR in Mice.

Authors:  Minghao Yan; Haibo Jin; Chun Pan; Hexing Hang; Dongmei Li; Xiaodong Han
Journal:  Mol Neurobiol       Date:  2022-06-22       Impact factor: 5.682

4.  Small molecule inhibition of RISC loading.

Authors:  Grace S Tan; Chun-Hao Chiu; Barry G Garchow; David Metzler; Scott L Diamond; Marianthi Kiriakidou
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

Review 5.  Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Mol Neurodegener       Date:  2015-04-08       Impact factor: 14.195

Review 6.  Emerging preclinical pharmacological targets for Parkinson's disease.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Oncotarget       Date:  2016-05-17

Review 7.  Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity.

Authors:  Vanesa Sanchez-Guajardo; Christopher J Barnum; Malú G Tansey; Marina Romero-Ramos
Journal:  ASN Neuro       Date:  2013-04-30       Impact factor: 4.146

Review 8.  Inflammation in Parkinson's Disease: Mechanisms and Therapeutic Implications.

Authors:  Marta Pajares; Ana I Rojo; Gina Manda; Lisardo Boscá; Antonio Cuadrado
Journal:  Cells       Date:  2020-07-14       Impact factor: 6.600

Review 9.  A New Insight into an Alternative Therapeutic Approach to Restore Redox Homeostasis and Functional Mitochondria in Neurodegenerative Diseases.

Authors:  Dong-Hoon Hyun; Jaewang Lee
Journal:  Antioxidants (Basel)       Date:  2021-12-21

10.  The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease.

Authors:  Hao Yu; Xiaojie Liu; Bixuan Chen; Casey R Vickstrom; Vladislav Friedman; Thomas J Kelly; Xiaowen Bai; Li Zhao; Cecilia J Hillard; Qing-Song Liu
Journal:  Cells       Date:  2021-12-16       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.